Effect of intraperitoneal aprotinin treatment in acute and chronic peritonitis.
Our results demonstrate that peritoneal absorption even of large amounts of fluid is not restricted in either acute or chronic peritonitis. According to investigations reported elsewhere, antibiotics administered intraperitonealy can be found quantitatively in the serum, if peritoneal absorption is not impaired. The retardation effect of proteinase inhibitor TRASYLOL on peritoneal absorption in peritonitis may indicate that proteolytic processes are necessary to break up the protein binding of antibiotics which only then are able to permeate the peritoneal wall. This may also pertain to other substances of pharmacologic activity, like toxins -lipoproteins, lipopolysaccharides- and medicaments. With respect to the clinical relevance of this effect it should be regarded as beneficial. Alternatively, the role of kallikrein/kinin-system for transmembranous absorption of proteins and protein split products has to be considered.
D000208:Acute Disease; D000818:Animals; D007611:Aprotinin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D007274:Injections, Intraperitoneal; D007583:Jejunum / Q000473:pathology; D007700:Kinetics; D008297:Male; D010538:Peritonitis / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D014031:Tobramycin / Q000097:blood
D007611:Aprotinin; D014031:Tobramycin